Navigation Links
Genetic Immunity to Present at 2008 BIO International Convention
Date:6/12/2008

rove the immunigenicity of antigens and induce effective immune responses. NanoComp has also demonstrated proof of concept with the DermaVir Patch, which includes HIV-specific plasmid DNA encoded antigens.

About Genetic Immunity(R)

Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical company establishing leadership in Nanomedicines for targeted immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. The Company aims to discover, develop and commercialize topically administered nanomedicines that can create new markets for treating infectious diseases, cancer and allergies. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. The DermaVir Patch, Genetic Immunity's lead nanomedicine candidate, is in Phase II clinical development and could be the first nanomedicine immune therapy for HIV-infected individuals. The DermaVir Patch has demonstrated excellent safety, immunogenicity and antiviral efficacy in preclinical studies. Phase I/II trials to date have confirmed safety and tolerability and indicate the induction of long-lasting HIV-specific memory T cells.

About the Nanomedicine Technology Platform

Genetic Immunity's nanomedicine immune amplification platform technology is comprised of two principal components: NanoComp and DermaPrep. NanoComp is a patented nanoformulation technology that includes disease-specific plasmid DNA encoded antigens. DermaPrep is the topical administration device that delivers NanoComp into a patient's lymph node dendritic cells to induce T cell mediated immune responses that can treat a broad spectrum of diseases. These two components together make up the DermaVir Patch. The plasmid DNA within DermaVir Patch's NanoComp nanoparticles is specific to HIV and topically delivered via DermaPrep to amplify the imm
'/>"/>

SOURCE Genetic Immunity
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
2. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
3. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
4. Presentation of Data on Progens Cancer Epigenetic Targets Platform
5. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
6. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
7. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
10. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
11. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...9 /PRNewswire-Asia/ -- ScinoPharm, a leading globa...PIs), announced that its,Tainan facility has recei...SafeBridge(R) Consultants, Inc. The Certification ...n the safe handling of potent active,pharmaceutica...ratories and,production areas used for the manufac...
(Date:11/19/2009)...wire/ -- Riverain Medical announced today that the...medical imaging distributor Christie Group to offe...t Xray CAD. The exclusive agreement will bring Day... Canadian market through Christie Group,s establis...hanced Chest Imaging increases the clarity of digi...
(Date:11/19/2009)... Ligon Discovery, Inc., which uses ...o find drugs against high-value targets, today ann...d by incTANK Ventures. The company will use the ca...hat will screen over 100 high-value disease protei...General Partner Christian Bailey joins the board. ...
Breaking Medicine Technology:ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Riverain Medical Partners With The Christie Group In Canada To Offer SoftView Enhanced Chest Imaging and OnGuard Chest X-Ray CAD Technologies 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3NeoVista Inc Announces Initial VIDION Shipments 60378 1NeoVista Inc Announces Initial VIDION Shipments 60378 2NeoVista Inc Announces Initial VIDION Shipments 60378 3SCM Microsystems Announces Results of Annual Meeting 10583 1SCM Microsystems Announces Results of Annual Meeting 10583 21 disease not 1 demographic 60373 11 disease not 1 demographic 60373 21 disease not 1 demographic 60373 3
...f ,First Generation, Antisense, BERKELEY HEIGHTS,...) announced the presentation of new data showing,t...s lead anticancer,compound, can be safely administ...usion. The new data were presented by Dr. Anthony ...s Accelerated Research Therapeutics,(START), and C...
...g Application for TREANDA by End of ...phalon, Inc. (Nasdaq:,CEPH) today announced positi...A(R) (bendamustine HCl) in patients with indolent ...nger responsive to treatment with,rituximab. The s... rate and,median duration of response, while demon...
Other Medicine Technology:Genasense(R) Can be Administered by Brief High-Dose IV Infusion 2Genasense(R) Can be Administered by Brief High-Dose IV Infusion 3Genasense(R) Can be Administered by Brief High-Dose IV Infusion 4Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma 2Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma 3Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma 4
(Date:11/21/2009)... -- Milvia Lopez, by her attorney MICHAEL STEWART ... Supreme Court, New York County, bearing Index # 1...opez underwent a routine transesophageal echocardi... used an HIV infected scope exposing her to HIV. ...ter being discharged from the procedure and arrivi...
(Date:11/21/2009)... credentialing software company IntelliSoft Group ... with Amerinet, Inc., the leading healthcare G.P.O...form quality care within the healthcare market. ,... -- ISG Group, LLC, doing business as IntelliSoft ... Inc., a leading national healthcare group purchas...
(Date:11/21/2009)... Group merges their practice with that of E. Steve... (PRWEB) November 21, 2009 -- The New Ha...Gibson, Dr. Dean Cloutier, Dr. John Plachtyna and ... practice with that of esteemed colleague Dr. E. S...ted to retire from dentistry in order to concentra...
(Date:11/20/2009)...re-USNewswire/ -- The American Academy of Actuari...orm legislation released this week to contain stro...ual coverage mandate. The actuaries said that an e...erse selection stemming from more restrictive issu...The individual mandate language should be strength...
(Date:11/20/2009)...wswire-FirstCall/ -- Rates of infection by the 200...ober, but the pandemic flu virus continues to be a...cluding the elderly, according to a new report by ... world,s leading provider of diagnostic testing, i... Quest Diagnostics Health Trends(TM) Report "Testi...
Breaking Medicine News(10 mins):Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:New Haven Dental Group Expands Their Vision 2Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3
...showed that slimmer people mostly commit suicide a...nd that depression level decreased as Body Mass In...t people who are overweighed felt very depressed b...ound that people who committed suicide had a lower...
...encephalitis in India’s Bihar State has taken a to...here is panic among the people of Bagaha District ... Health Minister of Bihar however seems to be unaw...brain caused by a virus. The district admini...
... American scientists has sparked new fears over th...le that they should eat no more than two portions ...lbany, part of New York State University, conclude... fed determine whether the health risks will outwe...
...Hempstead oil depot fire accident has been describ... engaged in putting out the blaze. The flames are ...ls.// Fears of a yet another explosion from a high...given. As many as 150 fire service personnel...
...cancer can be triggered by the common cold, accord... and brain tumors may be caused by relatively mino... flu. //This is all the more in the case of those ...may lead to the development of a vaccine which wil...
...n increase in demand for Palliative care for treat...rom Annual Survey of Hospitals, which has been rep...liative care is given to patients where chemothera...pid increase in demand for palliative care. Pall...
Other Medicine News:Health News:Salmon's own diet sure to affect yours 2Health News:Firefighters Continue To Battle Blaze 2
Epiplan-Neofluar objectives
... have been completely redesigned by Nikon allowing...lator inside the objective. That direction, once s...nge from 10x to 40x.,Apodized phase contrast objec...educe halos in the image by reducing internal refl...
...se immersion objective has a higher numerical aper...edia helps eliminate surface,reflections and provi...ent objective for fluorescence, brightfield and DI...s a correction collar that allows it to be used wi...
CFI Plan Achromat Series for Brightfield/Phase Contrast (DL)
Medicine Products: